FDA Wants Improved Products To Prevent Kidney Transplant Rejection
This article was originally published in The Pink Sheet Daily
Acute antibody-mediated rejection can be treated successfully 90 percent of the time, but designing a trial for another therapy might prove difficult..
You may also be interested in...
Lux Biosciences' Luveniq (voclosporin) for uveitis will undergo review by FDA's Dermatologic and Ophthalmic Drugs Advisory Committee on June 28.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.